Shared therapeutic targets for CKD and HF include the renin–angiotensin system (RAS), sodium‐glucose cotransporter 2 (SGLT2), mineralocorticoid receptor (MR) and glucagon‐like peptide‐1 (GLP‐1) receptor. The gene discussed is SLC5A2; the disease is chronic kidney disease.